Abivax (ABVX) SA announced the launch of an approximately $400M underwritten public offering consisting of a public offering of its American Depositary Share, ADSs, each representing one ordinary share of the company in the U.S. All securities to be sold in the offering will be offered by the company. Leerink Partners, Piper Sandler & Co. and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as lead manager, with BTIG and Van Lanschot Kempen acting as co-managers for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz
- Abivax price target raised to $101 from $45 at LifeSci Capital
- Abivax upgraded to Overweight from Equal Weight at Morgan Stanley
- Abivax upgraded to Overweight at Morgan Stanley after obefazimod data